Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yumeng Lu

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Acta Biochimica Et Biophysica Sinica|November 27, 2023
Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulationShuhan Jin, Bo Li, Bibo Zhang, et al.
Journal of Biomedical Science|May 13, 2022
Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myelomaYongsheng Xie, Yingcong Wang, Zhijian Xu, et al.
Haematologica|September 28, 2023
Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myelomaGege Chen, Xuejie Gao, Xinyan Jia, et al.
Leukemia|May 8, 2023
Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myelomaLi Xu, Yingcong Wang, Guanli Wang, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Acta Biochimica Et Biophysica Sinica|November 27, 2023
Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulationShuhan Jin, Bo Li, Bibo Zhang, et al.
Journal of Biomedical Science|May 13, 2022
Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myelomaYongsheng Xie, Yingcong Wang, Zhijian Xu, et al.
Haematologica|September 28, 2023
Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myelomaGege Chen, Xuejie Gao, Xinyan Jia, et al.
Leukemia|May 8, 2023
Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myelomaLi Xu, Yingcong Wang, Guanli Wang, et al.
Pageof 3